Eli Lilly to acquire Pfizer animal health parts
The animal health division of drugmaker Eli Lilly will acquire the rights to a portfolio of Pfizer products in Europe, including vaccines and feed additives. Terms of the deal were not disclosed.
Pfizer Animal Health has welcomed the signing of an agreement between Pfizer and Elanco, the animal health business unit of Eli Lilly and Company, under which Elanco will acquire European rights to a portfolio of certain Pfizer Animal Health and legacy Fort Dodge Animal Health products.
The products – including vaccines, parasiticides and feed additives – have been marketed by Pfizer and Wyeth.
As part of a deal, Elanco will take over the manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. As part of the deal, all Sligo employees will be offered positions with Elanco.
Elanco President Jeff Simmons said in a statement that the deal will allow the company to expand in Europe.
“The addition of this attractive portfolio of products and a world-class manufacturing facility is a natural fit for Elanco and positions us well for sustained growth,” said Simmons. “Through this acquisition, we will expand and diversify our European presence with new market-leading products,” he said.
The European Commission asked Pfizer Inc. to divest some of its assets after it bought drug and health company Wyeth for $68 bln last year.
Join 31,000+ subscribers
Subscribe to our newsletter to stay updated about all the need-to-know content in the poultry sector, three times a week.
